Cytosorbents (CTSO) Gains from Investment Securities (2013 - 2026)

Cytosorbents has reported Gains from Investment Securities for 13 years, with the latest figure at $50707.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 99.59% year-over-year to $50707.0; the trailing twelve-month figure through Mar 2026 stood at $50707.0 (down 99.59% YoY), and the FY2025 full-year result was $11.0 million, up 175.9% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $50707.0, down from $11.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $12.3 million in Q1 2025, with the low at $42499.0 in Q2 2022.
• Historically, Gains from Investment Securities has averaged $3.2 million across 5 years, with a median of $767690.5 in 2023.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities surged 3117.68% — and 2026, when it tumbled 99.59%.
• Cytosorbents' Gains from Investment Securities stood at $2.7 million in 2022, then soared by 294.46% to $10.5 million in 2023, then plunged by 62.24% to $4.0 million in 2024, then surged by 175.9% to $11.0 million in 2025, then tumbled by 99.54% to $50707.0 in 2026.
• The last three Gains from Investment Securities figures came in at $50707.0 (Q1 2026), $11.0 million (Q4 2025), and $787000.0 (Q3 2025), per Business Quant data.